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some improvements have been made, tar-
geted therapy continues to remain a chal-
lenge. Biodistribution studies of targeted 
drug-loaded particles have shown, at best, 
1–2% of total therapeutic administered 
reaching the desired target.[8,9]
Certain classes of particles may be 
effective in addressing one particular type 
of interactions or barriers, but none have 
addressed all barriers. Inorganic particles 
are arguably the most well defined car-
rier systems, usually having exceptional 
monodispersity with respect to size and 
shape.[2] They therefore can have some of the most reproduc-
ible in vivo results, and the ability to produce extremely small 
nanoparticles (less than around 5–6 nm in diameter) allows for 
renal clearance.[10] However, larger inorganic particles, which 
are not clearable renally or biodegradable, can accumulate in 
various tissues—although some studies show that there may 
be little acute toxicity, the long term effects are unknown.[2,11,12] 
Liposomes have excellent biocompatibility, but can be rather 
ineffective, have difficulty achieving adequate circulation and 
targeting, and be less stable than other classes of particles.[2,13] 
Polymer-based particles have the potentially for highly selective 
targeting, but also have short circulation times and, depending 
on the polymer, can be highly biocompatible or quite cyto-
toxic.[14,15] On the other hand, the diverse range of poly mers 
available affords particles made from them with a high degree 
of functionality.[16]
Incorporating multiple materials with different function-
alities into a multicompartmental particle may better address 
the barriers to effective therapy. Multicompartmental particles 
may afford multiple functionalities, theoretically addressing 
multiple barriers and thereby allowing for more effective 
therapy. Here we review some of the recent progress with the 
use of multicompartmental particles for medical applications, 
focusing on the areas of drug delivery, tissue engineering, and 
diagnostics.
2. Manufacturing of Multicompartmental Particles
Multicompartmental particulate carriers may be considered a 
class of anisotropic particles, the fabrication and study of which 
have become of great interest for numerous applications as well 
as a fundamental science. A number of methods have been 
developed for producing such particles. These methods may be 
broadly classified as sequential or simultaneous.
Sequential strategies involve step-wise fabrication 
of each individual compartment. Arguably the most 
Particulate materials are becoming increasingly used in the literature for 
medical applications, but translation to the clinical setting has remained 
challenging as many particle systems face challenges from in vivo barriers. 
Multicompartmental particles that can incorporate several materials in an 
individual particle may allow for more intricate control and addressing of 
issues that otherwise standard particles are unable to. Here, some of the 
advances made in the use of multicompartmental particles for medical appli-
cations are briefly described.
Multifunctional Nanocarriers
1. Introduction
Micro- and nanometer scale particulate carriers are considered 
to have great potential to address challenges in the treatment 
refractory diseases via their use in multiple areas including 
drug delivery and tissue engineering.[1–3] In attempting to 
address large-scale, reproducible fabrication of carriers with 
superior efficacy or potency, many different carriers have been 
made from a variety of materials. Despite advances in the 
design and fabrication of intricate particulate carriers, they have 
not realized their full potential in a clinical setting.
Many of the barriers to effective therapy may be attributed 
to complex interaction between particles and various physiolog-
ical, and pathophysiological, processes. It is particularly diffi-
cult to obtain long circulation times for particulate carriers due 
primarily to the immune system’s effectiveness in removing 
them from circulation. The reticuloendothelial system is espe-
cially adept at nonspecifically phagocytosing foreign particu-
late material, and several different materials of various shapes, 
mechanical properties, and surface properties have been devel-
oped to help prolong circulation times.[1,3–7] Additionally, while 
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common method involves beginning with the standard 
fabrication of an organic or inorganic particle, followed by 
modulation of their surface properties to selectively induce 
formation of subsequent compartments in particular 
locations on the seed particle, forming core–shell particles 
or other anisotropic particles (Figure 1a–c).[17–28] This pro-
cess can then be repeated to add additional compartments.[29] 
Another traditional method that is still used involves the 
swelling of polymeric particles with another monomer, fol-
lowed by polymerization—this process results in phase 
separation of the resultant polymerized phase, resulting in 
bicompartmental (Janus) particles.[30,31] Layer-by-layer (LbL) 
fabrication of particles is also a common method for making 
multicompartmental particles.[32–34]
More novel sequential methods have also emerged, 
including a modification of the particle replication in non-
wetting templates (PRINT) method developed by the DeS-
imeone group, in which multicompartmental particles are 
made by sequential partial filling and curing in the photo-
lithographed mold (Figure 1d); a similar method is described 
by Lee and co-workers but incorporates a dewetting solu-
tion before each curing step, allowing for the production of 
more spherically shaped multicompartmental particles.[35,36] 
Another unique method employs sequential electrospin-
ning of layers of fibers, followed by controlled deposition of 
photopolymer and crosslinking, and subsequent etching of 
exposed fibers.[37]
Simultaneous strategies generally are able to manufacture 
multicompartmenal particles in a single step, and tend to be 
more continuous processes whereas sequential strategies 
are often batch processed. A vast majority of these strategies 
employ microfluidics. One set of these fabrication methods 
involves the use of multiple immiscible phases containing dif-
ferent materials to generate droplets with multiple compart-
ments.[38–43] The Weitz group in particular has expanded on this 
concept to develop a number of unique multicompartmental 
architectures (Figure 2a).[40,41,43–48] These particles tend to have 
sizes on the order of 1–100 µm in diameter.
Another set of microfluidic-based techniques exploits the 
advantage of minimal diffusion across parallel streams, con-
taining various materials, in a laminar flow regime. Stop flow 
lithography employs spatially focused UV photopolymeriza-
tion of these streams to form multicompartmental particles 
(Figure 2b).[49–53] Another microfluidic method, developed by 
our group, is a modified electrospraying process called elec-
trohydrodynamic (EHD) cojetting (Figure 2c).[54–58] Multiple 
solutions are extruded in parallel under a laminar flow regime 
and a DC voltage is applied, forming a jet that rapidly evapo-
rates leaving solid multicompartmental particles or fibers (that 
may be further cryosectioned to make particles), mirroring the 
arrangement of the input streams.[56,59–61]
One other unique method of fabricating multicompart-
mental particles has been developed by the Mueller group and 
others that employs the self-assembly of multiblock copoly-
mers (Figure 2d).[62–68] Well-controlled synthesis of multiblock 
copolymers are capable of predictably self-assembling into 
particles such that different blocks of individual polymers 
associate with one another to form separate phases within 
an individual particle.[62] Of note, these formulations are 
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exquisitely dependent on the hydrophilic/hydrophobic bal-
ance between the polymer blocks as well as the solvent they 
are dispersed in.
3. Medical Applications
3.1. Drug Delivery
3.1.1. Temporal Control of Drug Release
Multiple compartments allow for more intricate control of drug 
release from a particle. Our group has incorporated multiple dif-
ferent functional materials to allow for varying measures of stim-
uli-controlled release. We have developed multicompartmental 
particles incorporating poly(lactic-co-glycolic acid) (PLGA) and 
polyethyleneimine (PEI) that allow for pH-dependent release 
of small interfering RNA (siRNA) such that it is released after 
endocytosis.[69] Via protonation of the secondary and ternary 
amines, the PEI compartment of individual particles can expand 
under acidic conditions of an endosome and ultimately results 
in the rupture of the endosome either physically or osmotically, 
known as the “proton sponge” effect.[70,71]
We have similarly shown pH-dependent release of iri-
notecan using PLGA/acetal-modified dextran multicompart-
mental particles.[72] The hydrophobic acetal-modified dextran 
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allows for loading of irinotecan—under acidic conditions, the 
acetal groups are cleaved resulting in water soluble dextran and 
release of the drug. We have also demonstrated light-responsive 
drug release by incorporating a photoacid generator into the 
same compartment as the acetal-modified dextran allows for 
UV light controlled release.[73] Additionally, near-infrared light 
responsive particles have been developed by He and co-workers 
that consist of doxorubicin loaded LbL particles modified with 
a gold half-shell that releases the chemotherapeutic agent on 
exposure to an 808 nm laser.[74]
Sequential release of multiple drugs has been shown by 
Weitz and co-workers via the use of fluorescent dyes loaded 
in multicompartmental polymersomes, consisting of a poly-
mersome within a polymersome using poly(lactic acid)-co-
poly(ethylene glycol) (PLA-PEG). Two distinct dyes are loaded, 
one within the inner polymersome compartment and another 
in the outer polymersome—the outer polymersome is mechan-
ically ruptured first, releasing one dye, and the inner polymer-
some ruptures after hydrolytic degradation releasing the second 
dye.[48] They also show the potential for multiple dye release by 
incorporating multiple inner polymersome compartments into 
the outer polymersome.
3.1.2. Multiple Drug Release
Simultaneous release of two or more drugs is another area of 
research avidly explored. Multicompartmental particles may 
have a potential advantage for this application by allowing for 
decoupling of the release of different drugs. For example, Bong 
and co-workers fabricate bicompartmental particles consisting 
of hydrolysable polymers (ketal groups) one of which is more 
crosslinked and thus has a longer half-life—these compart-
ments are loaded with fluorescent beads as a surrogate for 
drugs and release is shown to be slower and more prolonged 
from the crosslinked compartment (Figure 3a).[51]
Multicompartmental particles with a core–shell architecture 
have particularly been explored for releasing two distinct drugs. 
Vandamme and co-workers developed a core–shell polyacryla-
mide particle with ketoprofen loaded in the core and ranitidine 
in the shell via a microfluidic approach similar to that devel-
oped by the Weitz group.[75] Bahadur and co-workers showed 
release of doxorubicin and paclitaxel from iron oxide (Fe3O4)/
lipid core–shell nanoaprticles; made by a sequential approach, 
doxorubicin was loaded into Fe3O4 nanoparticles that were 
subsequently modified with a lipid shell containing pacli-
taxel.[76] Similarly, Loo and co-workers also showed release of 
doxorubicin and paclitaxel but from poly(lactic acid) (PLA)/
PLGA core–shell microparticle system (Figure 3b)—these par-
ticles were synthesized uniquely by oil-in-water emulsification 
where the PLA and PLGA dissolved in dichloromethane (DCM) 
phase-segregate as DCM evaporates.[77]
3.1.3. Combined Drug Delivery and Imaging
Multicompartmental particles are well suited for multifunc-
tional capabilities, and have specifically been used in simulta-
neous drug delivery and imaging applications. Incorporating 
inorganic materials often allow for facile fluorescence and/or 
MR-based imaging. For example, Zink and co-workers made 
core–shell iron oxide/silica nanoparticles loaded with camptoth-
ecin or paclitaxel, and demonstrated in vitro fluoresce imaging 
and delivery of these drugs—they additional demonstrated 
Adv. Healthcare Mater. 2018, 7, 1701319
Figure 1. Examples of multicompartmental particles made by sequential processes. a) Core–shell CaCO3 microparticles. Scale bar: 5 µm. Adapted with 
permission.[28] Copyright 2010, Wiley. b) Bicompartmental Au/MnO nanoparticles. Adapted with permission.[29] Copyright 2014, American Chemical 
Society. c) Core–shell iron oxide/silica nanoparticles. Adapted with permission.[78] Copyright 2008, American Chemical Society. d) Polymeric bicompart-
mental particles fabricated using particle replication in nonwetting templates (PRINT). Scale bars – SEM: 5 µm, fluorescence image: 20 µm. Adapted 
with permission.[35] Copyright 2009, Institute of Physics.
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the potential for MR imaging by ex vivo validation in a clini-
cally used MRI instrument.[78] Similarly, Sahu and co-workers 
developed Fe3O4–metal organic framework (core–shell parti-
cles loaded with paclitaxel, and showed in vitro efficacy against 
HeLa cells.[79] Other groups have similarly made multicom-
partmental particles that incorporate iron oxide to allow for 
imaging in addition to drug delivery.[80–85]
Our group has employed EHD cojetting to manufacture 
multicompartmental particles capable of simultaneous drug 
delivery and imaging. As discussed before, we developed 
PLGA/PEI bicompartmental particles that are capable of deliv-
ering siRNA—these particles also incorporate a fluorescent dye 
in the PLGA compartment, allowing for in vitro imaging as 
well as gene silencing.[69,86] We have also used acetal-modified 
dextran/PLGA bicompartmental particles to incorporate pir-
ibedil and glial cell derived neurotrophic factor for delivery to 
cochlea for applications to hearing loss (Figure 3c–e).[87]
These classes of multifunctional, multicompartmental par-
ticles are starting to be validated in in vivo models.[88–91] For 
example, Hammond and co-workers made a core–shell nano-
particle with a doxorubicin-loaded liposome, and an LbL shell 
containing siRNA and poly-l-arginine, with the last LbL layer 
using hyaluronic acid to improve the in vivo circulating half-
life (Figure 4).[91] They show efficacy, by measure of tumor 
volume, of these multicompartment particles in a mouse 
model of triple negative breast cancer. Of note, they demon-
strate combined use of a chemotherapeutic with siRNA—the 
siRNA was against MRP1, a multidrug resistance protein; 
using this siRNA improved efficacy compared to multicom-
partmental particles loaded with doxorubicin and a scrambled 
control siRNA.
3.2. Tissue Engineering
Multicompartmental particles are also increasingly used in 
tissue engineering applications. By having cells associate 
with a specific compartment, these particles may be able to 
develop novel tissues that more accurately mimic the aniso-
tropic architecture seen in native tissues and organs. Maeda 
et al. fabricates multicompartmental microparticles using a 
microfluidic approach where parallel streams of alginate solu-
tions are extruded using centrifugal force into a calcium chlo-
ride solution, allowing for rapid crosslinking—this approach 
allows for the inclusion of cells in one of the streams, shown 
by the incorporation of viable Jurkat cells in one compart-
ment of alginate-based bicompartmental microparticles.[92] 
Our group has also developed, by EHD co-jetting, core–shell 
Adv. Healthcare Mater. 2018, 7, 1701319
Figure 2. Examples of simultaneous fabrication processes. a) Multicompartmental particles via immiscible phases. Adapted with permission.[48] 
Copyright 2011, American Chemical Society. b) Stop flow lithography. Adapted with permission.[53] Copyright 2014, Nature Publishing Group. 
c) EHD cojetting. Adapted with permission.[54] Copyright 2005, Nature Publishing Group. d) Self-assembly of multiblock copolymers. Adapted with 
permission.[62] Copyright 2013, Nature Publishing Group.
1701319 (5 of 9)
www.advancedsciencenews.com www.advhealthmat.de
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
microparticles with a viable mammalian 
cell (NIH3T3) as the core.[93] These particles 
demonstrate the ability for cells to remain 
viable despite exposure to high DC voltages 
and high velocity jets.
Multicompartmental particles allow for 
the incorporation of chemically functional 
materials and therefore may display dif-
ferent surface properties over different cor-
responding compartments. Using this prin-
ciple, our group fabricated bioactuators using 
bicompartmenal cylinder-shaped microparti-
cles that display PEG on the surface of one 
compartment, and fibronectin on the other 
(Figure 5).[94] Primary rat cardiomyocytes 
were seeded onto these particles, selectively 
adhering to the fibronectin-displayed sur-
face of the microcylinders. Autonomous 
contractions of the cardiomyocytes trans-
duced mechanical displacement of the 
microcylinders.
3.3. Diagnostics
Multicompartmental particles have also 
started to be used in diagnostic applications. 
Several proofs of concept studies have been 
published demonstrating their use in proto-
type enzymatic reactions.[95–98] Skirtach and 
co-workers fabricated core–shell microparti-
cles, with a calcium carbonate (CaCO3) core 
with peroxidase and liposomal shell con-
taining Amplex Red.[99] Application of ultra-
sonic energy results in the rupture of the 
liposomes and release of Amplex Red, which 
reacts with hydrogen peroxidase (H2O2) via 
catalysis by peroxidase to produce the fluo-
rescent product resofurin.
Baumler and Georgieva expand upon 
this, developing multicompartmental parti-
cles that contain three enzymes for coupled 
enzymatic reactions (Figure 6).[100] In their 
particles, a CaCO3 contains Fe3O4 and horse 
radish peroxidase (HRP), glucose oxidase 
in an inner shell, and β-glucosidase in an 
outer shell. On exposure of these particles to 
Adv. Healthcare Mater. 2018, 7, 1701319
Figure 3. a) Release of fluorescent beads from bicom-
partmental hydrolysable particles with one compart-
ment crosslinked. Scale bar: 50 µm. Adapted with 
permission.[51] Copyright 2016, Wiley. b) Release 
of doxorubicin and paclitaxel from core–shell PLA/
PLGA microparticles. Scale bar: 30 µm. Adapted with 
permission.[77] Copyright 2015, Elsevier. c–e) Bicom-
partmental particles for cochlear imaging and drug 
delivery, with representative confocal imaging (c), 
release of piribedil (d), and imaging of cochlea after 
intracochlear delivery (e). Adapted with permission.[87] 
Copyright 2016, Wiley.
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a substrate for β-glucosidase, fluorescein-di-glucopyranoside, 
free fluorescein, and glucose are produced; the glucose in turn 
serves as a substrate for glucose oxidase, producing H2O2, 
which with Amplex Red can produce resorufin via HRP.
Another potential emerging area is pathogen sensing. 
Kim and co-workers shows the ability to detect Staphylococcus 
aureus in milk using core–shell iron oxide/Au nanoparti-
cles.[101] The particles display antibodies against S. aureus, 
causing aggregation of bacterial cells and particles if S. aureus 
is present in solution. Quantification of bacterial load is 
determined by degree of aggregation, which corresponds to a 
color change reflective of effective size of the aggregated Au 
compartments. While this is shown for identifying S. aureus 
in milk, this system may readily translated to determining 
bacterial load in biological specimens such as blood to deter-
mine bacteremia.
4. Conclusions
Here we have briefly reviewed a few of the advances in the 
use of multicompartmental particles for medical applications. 
The manufacturing of particles with more sophisticated and 
complex architectures have been made possible with the devel-
opment of more intricate and precise materials processing 
techniques. The use of photolithography and microfluidics 
have particularly allowed for such advancements, as shown, for 
example, by the PRINT, stop-flow lithography, and EHD cojet-
ting techniques.
Many of the studies involving these particles have focused 
on drug delivery and imaging. Multicompartmental particles 
allow for facile incorporation of both imaging contrast agents, 
especially for MRI and fluorescent imaging. Incorporation of 
functional materials, such as pH or light responsive ones, can 
Adv. Healthcare Mater. 2018, 7, 1701319
Figure 4. Multicompartmental nanoparticles with core–shell and LbL architectures made by Hammond and co-workers for simultaneous drug and 
siRNA delivery for triple negative breast cancer (TNBC). a) Design of multicompartmental particle. b) Multicompartmental particles with polystyrene 
core. c) Size of multicompartmental particles with liposome core at each LbL step. d) Release of doxorubicin and siRNA from particles. e) IV adminis-
tration of particles in mouse model of TNBC, showing localization to tumors, and interval decrease in signal. f) Quantitative measure of tumor volume 
over time for various formulations of particles with ones loaded with both doxorubicin and siRNA against MRP1 associated with least increase in tumor 
volume over time. Adapted with permission.[91] Copyright 2013, American Chemical Society.
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be used to provide particles with methods for controlled release 
of therapeutics including small molecule drugs and siRNA.
Other studies have shown the potential for multicompartmental 
particles for applications in tissue engineering and diagnostics. 
Our group has employed bicompartmental microcylinders for use 
as bioactuators, and others have used similar particles to incorpo-
rate various standard biological reactions, which may be expanded 
on in the future for quantification of biological substances.
As current materials processing techniques for the 
manufacture of multicompartmental particles advance, we may 
Adv. Healthcare Mater. 2018, 7, 1701319
Figure 5. Bioactuators made using EHD cojetting. a) Demonstration of selective binding of NIH3T3 cells to fibronectin (FN) adsorbed surfaces. 
Left confocal scale bar: 50 µm, right confocal scale bar: 20 µm. b) Selective binding of primary rat cardiomyocytes to one compartment with 
FN adsorbed to surface, and actuation of particle by contraction of cardiomyocytes. Scale bar: 20 µm. Adapted with permission.[94]  
Copyright 2015, Wiley.
Figure 6. Coupled enzymatic reaction within CaCO3-based core–shell microparticles. a) Diagram of enzyme cascade. b) Green fluorescent compart-
ments containing enzymes per above diagram, with production of resorufin in core after addition of glucose and H2O2. Adapted with permission.[100] 
Copyright 2010, American Chemical Society.
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continue to expect to see increasingly intricate particles that 
may be able to better address the barriers that have prevented 
particles from achieving their full potential in drug delivery and 
more.
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